Gilead Sciences stock is rallying today. But it's safe to say the reason why - remdesivir's four-figure price tag - is going to sicken you.
A potential coronavirus treatment developed by Gilead Sciences could cost up to 750% more than a flu vaccine. This could constrain containment.
The post Coronavirus Drug Could Cost 750% More Than a Flu Shot appeared first on CCN.com
Hopes of a treatment for the coronavirus powered one S&P 500 biotech company more than 3% higher as global stock markets plunged.
The post Why This S&P 500 Stock Is Defying the Brutal Coronavirus Plunge appeared first on CCN.com